Biblio Discovery — Demo Discovery Service

5 results for "3"

Showing 1–5 · 0.77 seconds · RSS

  1. Journal Article Full text

    A Neutralizing Monoclonal Antibody for Hospitalized Patients with Covid-19

    ACTIV-3/TICO LY-CoV555 Study Group

    New England Journal of Medicine · 2020 · English · OpenAlex Scopus

    BACKGROUND: LY-CoV555, a neutralizing monoclonal antibody, has been associated with a decrease in viral load and the frequency of hospitalizations or emergency department visits among outpatients with coronavirus disease 2019 (Covid-19). Data are needed on the effect of this antibody in patients…

  2. Journal Article

    Diagnosis and Treatment Protocol for Novel Coronavirus Pneumonia (Trial Version 7)

    (Released by National Health Commission & National Administration of Traditional Chinese Medicine on March 3, 2020); Pei-Fang Wei

    Chinese Medical Journal · 2020 · English · OpenAlex Scopus

    Since December 2019, multiple cases of novel coronavirus pneumonia (COVID-19) have been identified in Wuhan, Hubei. With the spread of the epidemic, such cases have also been found in other parts of China and other countries. As an acute respiratory infectious disease, COVID-19 has been included in…

  3. Journal Article Full text

    Tralokinumab plus topical corticosteroids for the treatment of moderate‐to‐severe atopic dermatitis: results from the double‐blind, randomized, multicentre, placebo‐controlled phase III ECZTRA 3 trial*

    Jonathan I. Silverberg; D. Toth; Thomas R.M. Bieber et al.

    British Journal of Dermatology · 2020 · English · OpenAlex Scopus

    BACKGROUND: Tralokinumab is a fully human monoclonal antibody that specifically neutralizes interleukin-13, a key driver of atopic dermatitis (AD). OBJECTIVES: To evaluate the efficacy and safety of tralokinumab in combination with topical corticosteroids (TCS) in patients with moderate-to-severe…

  4. Journal Article Full text

    Effect of Subcutaneous Semaglutide vs Placebo as an Adjunct to Intensive Behavioral Therapy on Body Weight in Adults With Overweight or Obesity

    Thomas A. Wadden; Timothy Silleck Bailey; Liana K. Billings et al.

    JAMA · 2021 · English · OpenAlex

    Importance: Weight loss improves cardiometabolic risk factors in people with overweight or obesity. Intensive lifestyle intervention and pharmacotherapy are the most effective noninvasive weight loss approaches. Objective: To compare the effects of once-weekly subcutaneous semaglutide, 2.4 mg vs…